CYDY’s struggle to fill the COVID19 trials will worsen with the addition of large, BP trials such as this one. I’m confident the 75 mild/moderate trial will fully enroll, but I standby my original opinion that the severe trial will never fully enroll.
Makes me ponder whether or not the 75 patients in the mild/moderate trial is going to be a sufficient for approval when these other BPs/biotechs are running 300-400 patient trials.